Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of FLOSEAL to standard of care for hemostasis in subjects undergoing total knee arthroplasty.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baxter Healthcare Corporation
• Treatments: Hemostatics

Criteria

Inclusion Criteria:

• Participant is 18 to 80 years of age inclusive at the time of screening

• Participant is planned for primary unilateral total knee arthroplasty

• Participant has signed the informed consent form

• Participant is in stable health (i.e., able to undergo surgery and participate in a follow-up program based on physical examination and medical history)

• Participant has a preoperative Hgb level > 10 g/dL

• If female of childbearing potential, the participant presents with a negative urine pregnancy test and agrees to employ adequate birth control measures for the duration of the study

• Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

• Participant has had a previous total or partial knee arthroplasty or any surgery on the knee within the previous 6 months

• Participant has osteonecrosis or arthrotomy within the last year

• Participant has prior or current hardware in target knee

• Participant has had injections in the knee:

1. Steroids within the 3 months prior to scheduled surgery,

2. Synvisc, Hyalin, etc. within the 6 months prior to scheduled surgery

• Participant has had general surgery within 3 months

• Participant has rheumatoid arthritis or any other inflammatory or traumatic bone injuries to the knee within the 12 months prior to scheduled surgery

• Participant has allergies to products of bovine origin

• Participant has a history of bleeding, platelet, or bone marrow disorders

• Participant has donated more than 1 unit of blood donation in the 3 weeks prior to surgery

• Participant has a history of a coagulation disorder

• Participant is currently taking dipyridamole/ASA (Aggrenox) and/or enoxaparin (Lovenox)

• Participant has been treated with aspirin or Warfarin (Coumadin) or clopidogrel (Plavix) within 7 days prior to surgery

• Participant is not permitted to remain without his/her anti-coagulant regimen (e.g. Plavix) for 48 hours postoperatively

• Participant has taken nonsteroidal anti-inflammatory agents or herbal supplements within 7 days of surgery

• Participant has a history of substance abuse (alcohol, drugs) or is an active smoker

• Participant has liver cirrhosis

• Participant has erythropoietin agonist/stimulating agent within 90 days prior to surgery

• Participant has an active infection or previous history of infection in the affected joint within the previous 6 months

• Participant has participated in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study